Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin

GlobeNewswire October 13, 2016

Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062

GlobeNewswire September 12, 2016

Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split

GlobeNewswire September 7, 2016

Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology’s 2nd International Conference on New Concepts

GlobeNewswire September 1, 2016

Sunesis to Present at Upcoming Investor Conferences

GlobeNewswire August 31, 2016

Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin

GlobeNewswire August 25, 2016

Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire July 29, 2016

Sunesis to Host Conference Call on July 29th to Discuss Second Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire July 21, 2016

Sunesis Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire July 5, 2016

Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting

GlobeNewswire June 13, 2016

Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting

GlobeNewswire June 6, 2016

Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development

GlobeNewswire June 1, 2016

Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June

GlobeNewswire May 25, 2016

Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association

GlobeNewswire May 19, 2016

Sunesis to Present at the 2016 UBS Global Healthcare Conference

GlobeNewswire May 18, 2016

Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire May 5, 2016

Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire April 28, 2016

Sunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

GlobeNewswire April 5, 2016

Sunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan

GlobeNewswire April 1, 2016

Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors

GlobeNewswire March 28, 2016